Newly Approved Hepatitis C Drug Has High Response Rates (FREE)

By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Nearly all patients with chronic hepatitis C virus (HCV) infection treated with glecaprevir-pibrentasvir achieved sustained virologic response after 12 weeks …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news